Cargando…

LPCAT1 promotes gefitinib resistance via upregulation of the EGFR/PI3K/AKT signaling pathway in lung adenocarcinoma

Currently, the mechanisms of epidermal growth factor receptor (EGFR) tyrosine kinase inhibitor (TKI) resistance have been a focus of clinical research. Despite that most of the mechanisms of acquired EGFR TKI resistance have been revealed, about 30% of non-small-cell lung cancer (NSCLC) cases have n...

Descripción completa

Detalles Bibliográficos
Autores principales:	Ding, Jianghua, Ding, Xinjing, Leng, Zhaohui
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Ivyspring International Publisher 2022
Materias:	Research Paper
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8990424/ https://www.ncbi.nlm.nih.gov/pubmed/35399731 http://dx.doi.org/10.7150/jca.66126

Ejemplares similares

LPCAT1 promotes brain metastasis of lung adenocarcinoma by up-regulating PI3K/AKT/MYC pathway
por: Wei, Chunhua, et al.
Publicado: (2019)

Etoposide/platinum plus anlotinib for patients with transformed small-cell lung cancer from EGFR-mutant lung adenocarcinoma after EGFR-TKI resistance: a retrospective and observational study
por: Ding, Jianghua, et al.
Publicado: (2023)

SKA3 promotes lung adenocarcinoma metastasis through the EGFR–PI3K–Akt axis
por: Hu, Dan-dan, et al.
Publicado: (2020)

Aumolertinib challenge as an optional treatment in advanced non small-cell lung cancer after osimertinib failure with epidermal growth factor receptor-sensitive mutation: A case series
por: Ding, Xinjing, et al.
Publicado: (2022)

Cyclooxygenase-2 mediates gefitinib resistance in non-small cell lung cancer through the EGFR/PI3K/AKT axis
por: Deng, Qin-fang, et al.
Publicado: (2020)

RNA methyltransferase METTL3 induces intrinsic resistance to gefitinib by combining with MET to regulate PI3K/AKT pathway in lung adenocarcinoma
por: Gao, Fangyan, et al.
Publicado: (2021)

Upregulation of CENPM facilitates lung adenocarcinoma progression via PI3K/AKT/mTOR signaling pathway: CENPM promotes lung adenocarcinoma progression
por: Liu, Chao, et al.
Publicado: (2021)

Linc01014 regulates gefitinib resistance in oesophagus cancer via EGFR‐PI3K‐AKT‐mTOR signalling pathway
por: Fu, Xiao, et al.
Publicado: (2019)

BYL719 reverses gefitinib-resistance induced by PI3K/AKT activation in non-small cell lung cancer cells
por: Yu, Yaya, et al.
Publicado: (2023)

Activity of pemetrexed and high-dose gefitinib in an EGFR-mutated lung adenocarcinoma with brain and leptomeningeal metastasis after response to gefitinib
por: Yuan, Ying, et al.
Publicado: (2012)

Lpcat3 deficiency promotes palmitic acid-induced 3T3-L1 mature adipocyte inflammation through enhanced ROS generation: Lpcat3 deficiency promotes adipocyte inflammation
por: Hu, Jiachun, et al.
Publicado: (2022)

KAT7 promotes radioresistance through upregulating PI3K/AKT signaling in breast cancer
por: Ma, Yan, et al.
Publicado: (2023)

Acquired Gefitinib-Resistant Mutation of EGFR in a Chemonaive Lung Adenocarcinoma Harboring Gefitinib-Sensitive Mutation L858R
por: Gow, Chien-Hung, et al.
Publicado: (2005)

HDGF promotes gefitinib resistance by activating the PI3K/AKT and MEK/ERK signaling pathways in non-small cell lung cancer
por: Han, Shuyan, et al.
Publicado: (2023)

Phase III study of gefitinib or pemetrexed with carboplatin in EGFR-mutated advanced lung adenocarcinoma
por: Patil, Vijay Maruti, et al.
Publicado: (2017)

LPCAT1 overexpression promotes the progression of hepatocellular carcinoma
por: He, Rong-Quan, et al.
Publicado: (2021)

Agmatinase promotes the lung adenocarcinoma tumorigenesis by activating the NO-MAPKs-PI3K/Akt pathway
por: Zhu, Hui-er, et al.
Publicado: (2019)

JMJD8 Promotes Malignant Progression of Lung Cancer by Maintaining EGFR Stability and EGFR/PI3K/AKT Pathway Activation
por: Zhang, Bo, et al.
Publicado: (2021)

Comprehensive Analysis of LPCATs Highlights the Prognostic and Immunological Values of LPCAT1/4 in Hepatocellular Carcinoma
por: Lin, Tong, et al.
Publicado: (2021)

Gefitinib induces lung cancer cell autophagy and apoptosis via blockade of the PI3K/AKT/mTOR pathway
por: ZHAO, ZHONG-QUAN, et al.
Publicado: (2016)

Lack of EGFR mutations benefiting gefitinib treatment in adenocarcinoma of esophagogastric junction
por: Wang, Wen-Ping, et al.
Publicado: (2012)

Fangchinoline exerts antitumour activity by suppressing the EGFR-PI3K/AKT signalling pathway in colon adenocarcinoma
por: Jiang, Fengqi, et al.
Publicado: (2021)

Anticancer Effects of Paris Saponins by Apoptosis and PI3K/AKT Pathway in Gefitinib-Resistant Non-Small Cell Lung Cancer
por: Zhu, Xinhai, et al.
Publicado: (2016)

Acquired Resistance of Lung Adenocarcinomas to Gefitinib or Erlotinib Is Associated with a Second Mutation in the EGFR Kinase Domain
por: Pao, William, et al.
Publicado: (2005)

Molecular heterogeneity assessment by next-generation sequencing and response to gefitinib of EGFR mutant advanced lung adenocarcinoma
por: Bria, Emilio, et al.
Publicado: (2015)

Achievement of Cure with Gefitinib in Advanced Lung Adenocarcinoma Harboring an Activating EGFR Mutation: A Case Report
por: Kuwata, Taiji, et al.
Publicado: (2016)

Knowledge-based mechanistic modeling accurately predicts disease progression with gefitinib in EGFR-mutant lung adenocarcinoma
por: L’Hostis, Adèle, et al.
Publicado: (2023)

Increased MIR31HG lncRNA expression increases gefitinib resistance in non-small cell lung cancer cell lines through the EGFR/PI3K/AKT signaling pathway
por: Wang, Bing, et al.
Publicado: (2017)

Daidzein Synergizes with Gefitinib to Induce ROS/JNK/c-Jun Activation and Inhibit EGFR-STAT/AKT/ERK Pathways to enhance Lung Adenocarcinoma cells chemosensitivity
por: Mhone, Thomas Gabriel, et al.
Publicado: (2022)

MiR-128 reverses the gefitinib resistance of the lung cancer stem cells by inhibiting the c-met/PI3K/AKT pathway
por: Jiang, Jingjin, et al.
Publicado: (2016)

CA916798 predicts poor prognosis and promotes Gefitinib resistance for lung adenocarcinoma
por: He, Jian, et al.
Publicado: (2023)

LPCAT2 controls chemoresistance in colorectal cancer
por: Cotte, Alexia Karen, et al.
Publicado: (2018)

LncRNA TP73-AS1 promoted the progression of lung adenocarcinoma via PI3K/AKT pathway
por: Liu, Chunfeng, et al.
Publicado: (2019)

UHMK1 promotes lung adenocarcinoma oncogenesis by regulating the PI3K/AKT/mTOR signaling pathway
por: Li, Yongmeng, et al.
Publicado: (2023)

TMEA, a Polyphenol in Sanguisorba officinalis, Promotes Thrombocytopoiesis by Upregulating PI3K/Akt Signaling
por: Li, Hong, et al.
Publicado: (2021)

NDAT Targets PI3K-Mediated PD-L1 Upregulation to Reduce Proliferation in Gefitinib-Resistant Colorectal Cancer
por: Huang, Tung-Yung, et al.
Publicado: (2020)

Gefitinib-induced skin ulceration in metastatic adenocarcinoma lung
por: Sathyanarayanan, Vishwanath, et al.
Publicado: (2014)

Curcumin Induces EGFR Degradation in Lung Adenocarcinoma and Modulates p38 Activation in Intestine: The Versatile Adjuvant for Gefitinib Therapy
por: Lee, Jen-Yi, et al.
Publicado: (2011)

CAV2 promotes the growth of renal cell carcinoma through the EGFR/PI3K/Akt pathway
por: Liu, Fu, et al.
Publicado: (2018)

LPCAT1 acts as an independent prognostic biomarker correlated with immune infiltration in hepatocellular carcinoma
por: Li, Lan, et al.
Publicado: (2022)

Cannot write session to /tmp/vufind_sessions/sess_o70s7264ijh1k1fuv175h2otgv